Default company panoramic image
E546b530 5513 43dd 98d8 9e4ea6f38242

Viper Therapeutics

Current snake antivenoms are unsafe and expensive. Viper Therapeutics has a novel, safe, and effective solution to this global unmet need.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Atlanta, GA, USA
  • Currency USD
  • Founded July 2011
  • Employees 2

Company Summary

The global supply of snake antivenoms currently consists of inferior products, in terms of both safety and efficacy, which are derived from animal serum. Viper Therapeutics has developed a novel platform for producing human antibody based snake anti-venoms to create safe and renewable treatments for snake envenomation. This platform will fill a global unmet public health need and has a potential multi-billion dollar market.


  • Default avatar
    Kevin L. Karem
    Founder and CEO

    Senior scientist with executive experience in strategic program planning, budget and personnel acquisition, and product development. Experienced in building domestic and international collaborations in laboratory research, medical epidemiology, public health response, and disease ecology. Private sector experience in business development, biotechnology, pediatric oncology, product development, knowledge management and program inception.

  • Default avatar
    Darin S. Carroll

    Senior research scientist with experience in developing and maintaining collaborations for public health improvement with US government, academic, and international agencies. Specialized experience in: design and implementation of laboratory studies and outbreak responses to infectious diseases; assessing public health and biosafety capacities of domestic and international public health laboratories; coordinating research of novel therapeutics.

Previous Investors

  • Default avatar
    Founders only